Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel

Colaboración

Año: 2021

Facey, KM; Espin, J; Kent, E; Link, A; Nicod, E; O'Leary, A; Xoxi, E; van de Vijver, I; Zaremba, A; Benisheva, T; Vagoras, A; Upadhyaya, S

Título: PHARMACOECONOMICS

• D1